| no |
title |
author |
magazine |
year |
volume |
issue |
page(s) |
type |
| 1 |
ABVD plus radiotherapy versus EVE plus radiotherapy in unfavorable stage IA and IIA Hodgkin's lymphoma: results from an Intergruppo Italiano Linfomi randomized study
|
Pavone, V.
|
|
|
19 |
4 |
p. 763-768
|
article
|
| 2 |
A new approach on bullous pemphigoid therapy
|
Saouli, Z.
|
|
|
19 |
4 |
p. 825-826
|
article
|
| 3 |
A phase II study of sorafenib in patients with chemo-naive castration-resistant prostate cancer
|
Chi, K.N.
|
|
|
19 |
4 |
p. 746-751
|
article
|
| 4 |
A phase II trial of CHOP chemotherapy followed by yttrium 90 ibritumomab tiuxetan (Zevalin) for previously untreated elderly diffuse large B-cell lymphoma patients
|
Zinzani, P.L.
|
|
|
19 |
4 |
p. 769-773
|
article
|
| 5 |
A randomised phase III study on capecitabine, oxaliplatin and bevacizumab with or without cetuximab in first-line advanced colorectal cancer, the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). An interim analysis of toxicity
|
Tol, J.
|
|
|
19 |
4 |
p. 734-738
|
article
|
| 6 |
Cancer and cancer-therapy related cognitive dysfunction: an international perspective from the Venice cognitive workshop
|
Vardy, J.
|
|
|
19 |
4 |
p. 623-629
|
article
|
| 7 |
Cancer mortality in the European Union, 1970–2003, with a joinpoint analysis
|
Bosetti, C.
|
|
|
19 |
4 |
p. 631-640
|
article
|
| 8 |
Can dynamic contrast-enhanced MRI (DCE-MRI) predict tumor recurrence and lymph node status in patients with breast cancer?
|
Bahri, S.
|
|
|
19 |
4 |
p. 822-824
|
article
|
| 9 |
Compassionate use of bevacizumab (Avastin®) in children and young adults with refractory or recurrent solid tumors
|
Benesch, M.
|
|
|
19 |
4 |
p. 807-813
|
article
|
| 10 |
Complete response to imatinib in relapsing pigmented villonodular synovitis/tenosynovial giant cell tumor (PVNS/TGCT)
|
Blay, J.-Y.
|
|
|
19 |
4 |
p. 821-822
|
article
|
| 11 |
EGFR FISH assay predicts for response to cetuximab in chemotherapy refractory colorectal cancer patients
|
Cappuzzo, F.
|
|
|
19 |
4 |
p. 717-723
|
article
|
| 12 |
Emerging therapeutic options for breast cancer chemotherapy during pregnancy
|
Mir, O.
|
|
|
19 |
4 |
p. 607-613
|
article
|
| 13 |
Estrogen-dependent cell signaling and apoptosis in BRCA1-blocked BG1 ovarian cancer cells in response to plumbagin and other chemotherapeutic agents
|
Thasni, K.A.
|
|
|
19 |
4 |
p. 696-705
|
article
|
| 14 |
European guidelines for quality assurance in breast cancer screening and diagnosis. Fourth edition—summary document
|
Perry, N.
|
|
|
19 |
4 |
p. 614-622
|
article
|
| 15 |
Favorable trends in cancer mortality in the European Union but no room for complacency
|
Boyle, P.
|
|
|
19 |
4 |
p. 605-606
|
article
|
| 16 |
First-line single-agent cetuximab in patients with advanced colorectal cancer
|
Pessino, A.
|
|
|
19 |
4 |
p. 711-716
|
article
|
| 17 |
Human equilibrative nucleoside transporter 1 (hENT1) protein is associated with short survival in resected ampullary cancer
|
Santini, D.
|
|
|
19 |
4 |
p. 724-728
|
article
|
| 18 |
In this issue
|
|
|
|
19 |
4 |
p. 603
|
article
|
| 19 |
KIT and PDGFRα mutations in 104 patients with gastrointestinal stromal tumors (GISTs): a population-based study
|
Braconi, C.
|
|
|
19 |
4 |
p. 706-710
|
article
|
| 20 |
Low-grade mucosa-associated lymphoid tissue lymphoma: a retrospective analysis of 97 patients by the Hellenic Cooperative Oncology Group (HeCOG)
|
Papaxoinis, G.
|
|
|
19 |
4 |
p. 780-786
|
article
|
| 21 |
MAPK overexpression is associated with anthracycline resistance and increased risk for recurrence in patients with triple-negative breast cancer
|
Eralp, Y.
|
|
|
19 |
4 |
p. 669-674
|
article
|
| 22 |
Metastases to the breast: role of fine needle cytology samples. Our experience with nine cases in 2 years
|
Fulciniti, F.
|
|
|
19 |
4 |
p. 682-687
|
article
|
| 23 |
Multicenter phase II trial of gefitinib first-line therapy followed by chemotherapy in advanced non-small-cell lung cancer (NSCLC): SAKK protocol 19/03
|
D'Addario, G.
|
|
|
19 |
4 |
p. 739-745
|
article
|
| 24 |
Non-Hodgkin’s lymphoma in very elderly patients over 80 years. A descriptive analysis of clinical presentation and outcome
|
Thieblemont, C.
|
|
|
19 |
4 |
p. 774-779
|
article
|
| 25 |
p27 and Skp2 immunoreactivity and its clinical significance with endocrine and chemo-endocrine treatments in node-negative early breast cancer
|
Ravaioli, A.
|
|
|
19 |
4 |
p. 660-668
|
article
|
| 26 |
Preoperative CA 15-3 and CEA serum levels as predictor for breast cancer outcomes
|
Park, B.-W.
|
|
|
19 |
4 |
p. 675-681
|
article
|
| 27 |
Prognostic factors for hematotoxicity of chemotherapy in aggressive non-Hodgkin’s lymphoma
|
Ziepert, M.
|
|
|
19 |
4 |
p. 752-762
|
article
|
| 28 |
Prognostic factors for local and distant control in Ewing sarcoma family of tumors
|
Rodríguez-Galindo, C.
|
|
|
19 |
4 |
p. 814-820
|
article
|
| 29 |
Proliferation accurately identifies the high-risk patients among small, low-grade, lymph node-negative invasive breast cancers
|
Baak, J.P.A.
|
|
|
19 |
4 |
p. 649-654
|
article
|
| 30 |
p53 status correlates with histopathological response in patients with soft tissue sarcomas treated using isolated limb perfusion with TNF-α and melphalan
|
Muret, J.
|
|
|
19 |
4 |
p. 793-800
|
article
|
| 31 |
Randomized phase II study of irinotecan, leucovorin and 5-fluorouracil (ILF) versus cisplatin plus ILF (PILF) combination chemotherapy for advanced gastric cancer
|
Park, S.H.
|
|
|
19 |
4 |
p. 729-733
|
article
|
| 32 |
Remission of diabetes while on sunitinib treatment for renal cell carcinoma
|
Templeton, A.
|
|
|
19 |
4 |
p. 824-825
|
article
|
| 33 |
Table of Contents
|
|
|
|
19 |
4 |
p. ii-iv
|
article
|
| 34 |
Temozolomide plus pegylated interferon alfa-2b as first-line treatment for stage IV melanoma: a multicenter phase II trial of the Dermatologic Cooperative Oncology Group (DeCOG)
|
Spieth, K.
|
|
|
19 |
4 |
p. 801-806
|
article
|
| 35 |
The impact of a false-positive MRI on the choice for mastectomy in BRCA mutation carriers is limited
|
Hoogerbrugge, N.
|
|
|
19 |
4 |
p. 655-659
|
article
|
| 36 |
Treatment outcome and survival in participants of phase I oncology trials carried out from 2003 to 2006 at Institut Gustave Roussy
|
Italiano, A.
|
|
|
19 |
4 |
p. 787-792
|
article
|
| 37 |
Weight change and cancer risk in a cohort of more than 65000 adults in Austria
|
Rapp, K.
|
|
|
19 |
4 |
p. 641-648
|
article
|
| 38 |
Why i.p. therapy cannot yet be considered as a standard of care for the first-line treatment of ovarian cancer: a systematic review
|
Swart, A.M.C.
|
|
|
19 |
4 |
p. 688-695
|
article
|
Journal description